for the period ended 31 December 2008
CALGARY, Feb. 27 /CNW/ - Epicore BioNetworks Inc. experienced strong business growth in quarter two fiscal 2009 despite challenging market conditions and severe turmoil in world economies. Revenue increased by 16% compared to prior year quarter two and set a new quarter two record. Some highlights were:
- Increased net income to $0.30 million compared to $0.11 in prior year
quarter two.
- Achieved net income as a percentage of sales revenue of 13%.
- Grew basic and diluted earnings from $0.003 per share in prior year
to $0.005.
- Grew sales revenues by $0.13 million (16%) beating a prior year
quarter two record.
- Increased total stockholders equity to $2.3 million from $2.2 million
in the last quarter and $1.6 million in prior year quarter two.
- Cash balance of $0.6 million higher than prior year quarter two of
$0.3 million.
Aquaculture remains the Company's strongest market sector, producing 96% of total sales. Epicore biotechnology and specialty feed technology offer answers to problems of pollution, disease and poor nutrition in aquaculture operations around the world and the Epicore product range offers strong value to a growing customer base. Quarter two saw a significant increase in Epicore agricultural sales and revenue from this growing sector.
Latin America was the largest sales region in the period. Distributors in Mexico and India made major contributions to fiscal 2009 quarter two results.
Epicore gross profit increased the same percentage as sales increased because gross margin was maintained. Operating expenses were 1% lower than prior year. Revenue growth resulted in a higher provision for income taxes, which were partially decreased by our accumulated net operating losses. The Company generated a net income of $0.12 million, an 82% increase over the prior year quarter two.
(US$) 2008 2007
---- ----
Sales 910,000 782,000
Gross Profit 554,000 477,000
Expenses 389,000 391,000
Other Income (Expense) (9,000) (8,000)
Income Taxes 36,000 12,000
Net Income 120,000 66,000
Cash at the end of December was $0.6 million, an increase of $0.2 million compared to prior year but a decrease of $0.1 million from fiscal 2008 quarter one; this was mainly due to working capital increases. With these funds, expected sales revenue growth and continued control of operating costs, management expects there will be sufficient cash to meet the fiscal year's financial requirements. Additional funds will go toward expansion of aquaculture and environmental remediation marketing efforts and the continuing investigation of new strategies for enhancing shareholder value.
The Company is pleased to announce that Jean C. Messier, who retired from the board of directors in January, has agreed to provide consulting services to Epicore. Mr. Messier has extensive experience in sales and marketing, which during his tenure as a director proved valuable to the Company.
The financial statements of the Company have been prepared in accordance with Canadian GAAP. Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). (The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.)
This press release contains forward-looking statements that involve significant risks and uncertainties, such as the one about having sufficient cash to meet the fiscal year's financial requirements. This statement is based on the assumption that the Company's sales will continue as expected. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the development plans of the Company and the expected timing and results of such development. We can provide no assurance that such development will proceed as currently anticipated or that the expected timing or results of such development will be realized. We are subject to various risks, including the uncertainties of product development, markets for our products and regulatory review, our need for additional capital to fund our operations, our reliance on collaborative partners, our history of losses, and other risks inherent in the biotechnology industry.